Ajanta Pharma

What Ajanta Pharma does

Ajanta Pharma Limited is a specialty pharmaceutical company headquartered in Mumbai, India, founded in 1979 and publicly traded on Indian stock exchanges (NSE/BSE) under the ticker AJANTPHARMA. The company develops, manufactures, and markets branded generic and generic finished dosage formulations across three core business segments: India Branded Generics (Cardiology, Dermatology, Ophthalmology, Pain Management, Nephrology, and Gynaecology — 350+ products with over 50% first-to-market, ranked 24th in India per IQVIA March 2026), Emerging Markets Branded Generics (33+ countries across Africa, South-East Asia, Central Asia, and Middle East with 250+ brands), and US Generics through subsidiary Ajanta Pharma USA Inc. (49 commercialized ANDAs plus 19 awaiting FDA approval).

The company's technology foundation is formulation chemistry and complex drug development, supported by 850+ scientists at a 100,000 sq. ft. R&D facility in Mumbai and seven manufacturing facilities in India (six finished formulation facilities plus one captive API plant), with US FDA and WHO GMP approvals at Paithan and Dahej. Notable technical capabilities include extended-release formulations (Met XL — first generic extended-release Metoprolol in India), triple-drug combinations (Rosutor Gold — first combination of Rosuvastatin, Aspirin, and Clopidogrel), and fast-onset ophthalmic formulations (Alcarex — 3-minute vs 15-minute onset).

The business model operates across three revenue streams: India distribution via field sales force through pharmacy and healthcare channels, emerging markets via own dedicated sales teams in each geography, and US market via subsidiary working with major US distributors. FY2025-26 consolidated revenue reached ₹5,453 crore (17% YoY growth) with PAT of ₹1,056 crore (crossing the ₹1,000 crore threshold for the first time) and Adjusted EBITDA of ₹1,498 crore. Recent strategic actions include a December 2025 in-licensing agreement with Biocon to commercialize semaglutide in 26 emerging markets.

Name

Ajanta Pharma

Legal name

Ajanta Pharma Limited

Website

https://ajantapharma.com

Company type

Public

Founded year

1979

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Ajanta Pharma is a publicly listed Indian specialty pharmaceutical company manufacturing branded generic and generic formulations across India, 33+ emerging markets, and the USA. It operates 7 manufacturing facilities and 850+ scientist R&D, generating ₹5,453 crore FY26 revenue across cardiology, dermatology, ophthalmology, and other therapeutic segments.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

Keywords

• Specialty pharmaceuticals
• Branded generics
• Generic medicines
• Pharmaceutical formulations
• Active pharmaceutical ingredients

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices12 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. India Branded Generics: Revenue from branded generic medicines sold in India across specialty therapeutic segments including Cardiology, Dermatology, Ophthalmology, Pain Management, Nephrology, and Gynaecology. Ranked 24th in India as per IQVIA March 2026.
2. Emerging Markets - Branded Generics: Revenue from branded generics in 33+ emerging markets across Africa, South-East Asia, Central Asia and Middle East. Over 250 brands with significant market shares and leadership positions.
3. USA Generics: Revenue from generic pharmaceutical products in US market through subsidiary Ajanta Pharma USA Inc. 49 ANDA approvals commercialized with 19 awaiting FDA approval. US Generics segment grew 49% in FY26.
4. Semaglutide Partnership: In-licensing agreement with Biocon to market semaglutide in 26 emerging markets across Africa, Middle East, and Central Asia, expected to contribute ₹200 crore in FY28E

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Ajanta Pharma manufactures and markets specialty pharmaceutical finished dosage formulations across three business segments: India Branded Generics (Cardiology, Dermatology, Ophthalmology, Pain Management, Nephrology, Gynaecology), Emerging Markets Branded Generics in 33+ countries, and USA Generics through subsidiary Ajanta Pharma USA Inc. The company produces 600+ products in multiple dosage forms (tablets, capsules, sterile eye drops, injectables, ointments, creams, oral liquids) from 7 manufacturing facilities, with over 50% of India products being first-to-market.

Product overview

Ajanta Pharma is a specialty pharmaceutical company that operates three distinct business segments: (1) India Branded Generics covering Cardiology, Dermatology, Ophthalmology, Pain Management, Nephrology, and Gynaecology with 350+ products (50%+ first-to-market) ranking 24th in India; (2) Emerging Markets Branded Generics across 33+ countries in Africa, Asia, and Middle East with 250+ brands; and (3) USA Generics with 49 commercialized ANDAs and 19 awaiting approval. The company manufactures 7 different dosage forms (tablets, capsules, sterile eye drops, injectables, ointments/creams, oral liquids, dry powder suspension) across 7 facilities in India, with US FDA and WHO approved sites at Paithan and Dahej.

Differentiator

Problem solved

Functional benefit

Brands

• Met XL: Flagship anti-hypertensive brand, first generic extended-release formulation of Metoprolol launched in India
• Rosutor Gold
• Alcarex
• Bimat
• Feburic

Products and services

• Met XL

Quantifiable outcome

• Revenue crossed ₹5,000 crore milestone at ₹5,453 crore in FY2025-26
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• BioconcoreStrategic or Co-development Partner · 2 January 2026Ajanta Pharma plans to launch generic semaglutide in Asia and Africa markets through partnership with Biocon, positioning itself in the rapidly growing metabolic therapy market. The collaboration is part of Ajanta's strategy to expand into chronic therapy markets following the patent expiry of semaglutide.
• BioconcoreOEM/ Whitelabel/ Licensing Partner · 23 December 2025Ajanta Pharma entered into an in-licensing agreement with Biocon to market semaglutide (a GLP-1 receptor agonist for diabetes and weight management) in 26 emerging markets across Africa, Middle East, and Central Asia. Under the agreement, Biocon manufactures and supplies semaglutide while Ajanta handles commercialization in select markets. The deal is expected to generate ₹200 crore in revenue by FY28E with estimated EBITDA margin of 50-55%. Regulatory approvals expected in late 2026 or early 2027.
• BioconcoreOEM/ Whitelabel/ Licensing Partner · 23 December 2025Biocon out-licensed its Semaglutide diabetes drug to Ajanta Pharma for exclusive marketing in 23 countries and semi-exclusive marketing in 3 additional countries across Africa, Middle East and Central Asia. This strategic move leverages Ajanta's distribution infrastructure in emerging markets for the rapidly growing GLP-1 market.

Scale indicators19 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Cipla: Indian specialty pharmaceutical manufacturer with comparable India branded-generics, emerging-markets (Africa/Asia) and US generics franchises. Direct overlap in cardiology, respiratory and chronic therapy segments.
• Glenmark Pharmaceuticals: India-headquartered specialty pharma with branded generics in India and emerging markets plus a US generics business. Comparable therapeutic-segment focus and own manufacturing footprint.
• Aurobindo Pharma: Large Indian pharma with deep US generics presence (extensive ANDA portfolio) and growing emerging-markets franchise. Direct overlap in generic finished dosage forms and US distribution.
• Torrent Pharmaceuticals: Indian specialty pharma focused on branded generics in cardiology, dermatology and gastroenterology in India plus emerging markets. Closely aligned therapeutic-segment strategy.
• Alkem Laboratories: Indian specialty pharma with branded generics in India and US generics presence. Direct peer on the India specialty-pharma axis with similar therapeutic-segment breadth.
• Cadila Healthcare (Zydus): Indian pharma with branded generics in India, US generics franchise and emerging-markets operations. Comparable scale, dosage-form breadth and regulatory footprint.
• Ipca Laboratories: Indian specialty pharma with branded generics in India and emerging markets plus US generics. Overlap in dosage forms (tablets, injectables) and chronic-therapy segments.
• Mankind Pharma: Leading Indian branded-generics company with strong domestic sales force. Comparable field-sales-led GTM model and India specialty positioning across multiple therapeutic areas.
• Alembic Pharmaceuticals: Indian pharma with India branded generics and US generics (ANDA) business. Comparable specialty-pharma positioning with India manufacturing and USFDA-approved sites.
• Lupin Limited: Indian specialty pharma with major US generics presence and India/emerging-markets branded-generics. Closely comparable on US ANDA pipeline depth and India specialty portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ajantapharmaltd
• YouTubeyoutube.com/channel/UCQ62tZLFNUcIfYMlkfmOs2w
• Facebookfacebook.com/ajantapharmaltd
• LinkedInlinkedin.com/company/ajanta-pharma-ltd
• Instagraminstagram.com/ajanta_pharma

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ajanta Pharma